Clinical trial

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

NCT04322617

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2020-03-24

PhasePHASE2 / PHASE3

Study timeline

Study start (actual)2020-03-24Date precision: day

Registry last updated2024-06-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

Anlotinib plus the same Immune Checkpoint Inhibitors.DRUG

Anlotinib plus the new Immune Checkpoint Inhibitors.DRUG

AnlotinibDRUG

Sponsors & collaborators

Hunan Province Tumor Hospitallead sponsor

Mapped research locations

ChangshaHunan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04322617 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.